The discussion around nicotine pouches has, for some time now, been one of the hottest topics in tobacco harm reduction. Critics often describe these products as just another strategy from Big Tobacco to draw in a new wave of nicotine users. However, more and more evidence points to a different story: nicotine pouches are increasingly popular among adult smokers looking for a safer alternative to traditional cigarettes.
Meanwhile, perhaps fed by all the suspicion surrounding the products, the difference between public health outcomes and regulatory actions has rarely been this stark in Europe. Recently, France confirmed it is still okay to bring tobacco-containing snus into the country for personal use, while nicotine pouches that do not even contain tobacco are completely banned. For many consumers, this difference is so ridiculous that it would be comedic if it didn’t have such a negative effect on their lives. It is puzzling that a product with tobacco can be allowed while a tobacco-free version of pretty much the same product faces such strict restrictions.
This contradiction has become increasingly difficult to reconcile with the experience of Sweden, the first country in the world to achieve official smoke-free status, defined as smoking prevalence below 5%. Swedish public health outcomes are equally remarkable. The country records the lowest rates of smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease, across Europe. Researchers, public health specialists and harm reduction advocates have repeatedly pointed to widespread adoption of snus, nicotine pouches and other reduced-risk nicotine products as a key factor behind this achievement.
Dismissing what is staring them straight in the face
Yet rather than celebrating Sweden’s success, many international tobacco control organisations continue to dismiss or downplay the role of nicotine alternatives. Critics often focus on industry involvement, marketing practices or theoretical concerns about youth uptake while paying comparatively little attention to the real-world public health outcomes that have emerged in Sweden over several decades.
Sadly, the disconnect between how these products are generally portrayed and the results they deliver is not narrowing. Sensational headlines often imply that nicotine pouches are part of a strategy to hook kids on nicotine or portray them as an impending public health crisis. These stories typically overlook a key detail: nicotine pouches don’t contain tobacco, involve no burning, produce no smoke, and eliminate many harmful by-products associated with smoking-related diseases.
Moreover, the reason why nicotine pouches have become so popular is as clear as day. They provide adult smokers with a discreet, smoke-free, and vapour-free way to get their nicotine in situations where smoking and vaping just aren’t practical. Unlike cigarettes, they don’t create second-hand smoke. And compared to vaping products, they don’t need batteries, chargers, or liquid refills. The simplicity and convenience of the products are huge pluses.
The FDA acknowledges the harm reduction potential of ZYN
Thankfully, some regulators are starting to see the potential in nicotine products. In a noteworthy development, the US Food and Drug Administration (FDA) recently gave the green light for Philip Morris International to market certain ZYN nicotine pouch products with reduced-risk claims. The agency acknowledged that completely switching from cigarettes to these pouches could significantly cut down on exposure to harmful toxins tied to smoking, which might benefit public health overall. Given that FDA approvals require thorough scientific review, they represent one of the strongest regulatory endorsements for a nicotine product.
Simultaneously, nicotine is grabbing the attention of the international community. The Republic of Palau has officially asked for a review of nicotine under the 1971 UN Convention on Psychotropic Substances, which has led to an evaluation by the World Health Organization’s Expert Committee on Drug Dependence. After banning vapes in 2023, Palau argues that regulators have focused too much on specific products while neglecting nicotine as the common underlying factor.
This WHO review aims to investigate nicotine’s potential for addiction, its effects on public health, and its therapeutic uses, all while considering the rise of synthetic nicotine and new delivery methods. And while placing nicotine under international drug control would (hopefully) encounter significant political, scientific, and practical hurdles, this initiative shows how swiftly changing nicotine markets are pushing policymakers to rethink long-standing regulatory approaches.
Nicotine addiction fears should not eclipse smoking cessation benefits
Meanwhile, harm reduction advocates keep highlighting that conversations about nicotine addiction must not overshadow the critical differences in risk among various nicotine products. The serious health problems linked to smoking are due to inhaling toxic substances produced during combustion rather than from nicotine itself. Treating cigarettes, nicotine pouches, snus, and pharmaceutical nicotine products as if they all carry the same risks would ignore decades of scientific research and could undermine efforts to help people quit smoking.
Yet, critics argue that the rapidly expanding market for nicotine pouches appears more like aggressive industry growth than real consumer demand. They often point out rising sales figures, eye-catching packaging, and a variety of flavours as proof of marketing strategies aimed at luring young people. Recently, the Isle of Man took steps to ban the products to those under 18, a move that has gained wide support. Age restrictions are generally accepted within the harm reduction community and align with the idea that nicotine products should be meant for adults only. Protecting young people while ensuring adults have access need not be at odds; both can happen simultaneously.
For policymakers seeking to reduce smoking-related disease, the central question should be whether nicotine pouches represent a substantially lower-risk alternative to smoking. Increasingly, evidence suggests the answer is yes. And while many will likely continue to pursue policies driven largely by precautionary fears and distrust of industry, they can readily examine the outcomes achieved in countries that have embraced harm-reduction products.
Sweden’s results, combined with growing regulatory recognition by authorities such as the FDA, suggest that nicotine pouches deserve to be evaluated for their public health potential rather than on assumptions that often dominate the debate. If the ultimate goal is reducing smoking-related illness and death, evidence-based harm reduction should remain at the centre of the conversation.
